Shanghai ZJ Bio-Tech Co. Ltd. A Total Assets
Shanghai ZJ Bio-Tech Co. Ltd. A total assets. Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) holds total assets worth CN¥3.66 Billion CNY (≈ $535.03 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shanghai ZJ Bio-Tech Co. Ltd. A (688317) total market value for the company's overall valuation and market capitalisation.
Total Assets of Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
Total assets of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See 688317 live share price for real-time trading data and today's change.
Shanghai ZJ Bio-Tech Co. Ltd. A - Asset Composition Analysis
Shanghai ZJ Bio-Tech Co. Ltd. A Total Assets Breakdown (December 2025)
Shanghai ZJ Bio-Tech Co. Ltd. A total assets breakdown as of December 2025. Shanghai ZJ Bio-Tech Co. Ltd. A's total assets of CN¥3.66 Billion consist of 79.3% current assets and 20.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 67.8% |
| Accounts Receivable | CN¥31.24 Million | 0.8% |
| Inventory | CN¥45.57 Million | 1.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥7.04 Million | 0.2% |
| Goodwill | CN¥5.40 Million | 0.1% |
Asset Composition Trend (2013–2025)
This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shanghai ZJ Bio-Tech Co. Ltd. A working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai ZJ Bio-Tech Co. Ltd. A's current assets represent 79.3% of total assets in 2025, an increase from 48.5% in 2013.
- Cash Position: Cash and equivalents constituted 67.8% of total assets in 2025, up from 14.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 1.2% of total assets.
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai ZJ Bio-Tech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥2.34 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$9.96 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
Shanghai ZJ Bio-Tech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.38 | 22.67 | 8.44 |
| Quick Ratio | 25.04 | 22.25 | 7.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.76 Billion | CN¥2.82 Billion | CN¥2.95 Billion |
Shanghai ZJ Bio-Tech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai ZJ Bio-Tech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | CN¥3.76 Billion |
| Market Capitalization | $456.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai ZJ Bio-Tech Co. Ltd. A's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai ZJ Bio-Tech Co. Ltd. A's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
The table below shows the annual total assets of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.76 Billion ≈ $550.76 Million |
-0.69% |
| 2024-12-31 | CN¥3.79 Billion ≈ $554.59 Million |
-6.98% |
| 2023-12-31 | CN¥4.07 Billion ≈ $596.18 Million |
-14.12% |
| 2022-12-31 | CN¥4.74 Billion ≈ $694.17 Million |
+11.50% |
| 2021-12-31 | CN¥4.25 Billion ≈ $622.59 Million |
+126.36% |
| 2020-12-31 | CN¥1.88 Billion ≈ $275.04 Million |
+192.80% |
| 2019-12-31 | CN¥641.93 Million ≈ $93.93 Million |
+10.75% |
| 2018-12-31 | CN¥579.64 Million ≈ $84.82 Million |
+12.31% |
| 2017-12-31 | CN¥516.12 Million ≈ $75.52 Million |
-1.98% |
| 2016-12-31 | CN¥526.57 Million ≈ $77.05 Million |
+33.55% |
| 2015-12-31 | CN¥394.29 Million ≈ $57.70 Million |
+97.51% |
| 2014-12-31 | CN¥199.63 Million ≈ $29.21 Million |
+17.58% |
| 2013-12-31 | CN¥169.78 Million ≈ $24.84 Million |
-- |
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.